Species

Therapeutic Area

Highlighted

NCG-hIL2 Mouse

NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt-H11em1Cin(CAG-hIL2)/GptCrl

NCG-hIL2
AT A GLANCE

Coat Color

White

Strain Code

722

Ideal For

Oncology, immunology, infectious disease, graft vs. host disease, diabetes, regenerative medicine, human organ transplantation and humanizable NCG model

Produced In

United States
Description

NCG-hIL2 is a triple immunodeficient NCG mouse expressing human IL-2 cytokine. IL-2 promotes the expansion and activation of lymphocytes and natural killer cells.  OriginThe NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by introducing the human IL-2 gene creating the NCG-hIL2. The strain was transferred to Charles River in 2022.